News

Plazomicin Granted FDA Breakthrough Therapy Designation

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) — Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for plazomicin, Achaogen’s lead product candidate being developed for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

2017-06-20T13:04:11+00:00